Delivery Order SPE2DB20D2001-SPE2DB22FM33Y
- Not listed
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,143.47 firm-fixed-price contract is for the delivery of 180 units of 800 mg delayed-release mesalamine tablets, a medication used to treat gastrointestinal conditions. The contract has an ultimate completion date of October 20, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of 180 800-milligram delayed-release mesalamine tablets. The $6,145.71 contract has an ultimate completion date of June 11, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,608.15 firm fixed-price delivery order, with a completion date of December 28, 2021, is for the supply of Mesalamine DR 1.2 GM Tablet 120S, a prescription medication. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,560,783,304 tablets of Mesalamine DR 1.2 GM, a pharmaceutical product, with a ceiling value of $9,696.97 and a completion date of May 2, 2023. The contract is a Firm Fixed Price Delivery Order, and there is no set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,147.79, is for the delivery of Mesalamine delayed-release 1.2 gram tablets in quantities of 120 tablets per bottle. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating it was awarded through full and open competition. AmerisourceBergen Drug Corp is a subsidiary of the...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,368.24, is for the delivery of 120 units of Mesalamine DR 1.2 GM Tablets. This is a firm fixed-price delivery order contract with a completion date of May 5, 2023. The contract is not designated as a set-aside award. Amerisourcebergen holds a significant Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,669.74 fixed-price contract is for the delivery of 120 tablets of 1.2 gram Mesalamine delayed-release medication. The contract has a completion date of February 9, 2023 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of Mesalamine DR 400 mg capsules. The $1,918.44 firm-fixed-price contract has an ultimate completion date of September 19, 2022. Amerisourcebergen is a major pharmaceutical distributor that holds a $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range...
- This is a delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Mesalamine 800 mg delayed-release (DR) tablets. The $1,946.81 firm-fixed-price contract has an ultimate completion date of August 19, 2024 and does not utilize a set-aside. AmerisourceBergen holds an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999 through December 2025 for delivering a...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 120 tablets of the medication Mesalamine Delayed-Release 1.2 gram, with a ceiling value of $2,180.50 and a completion date of June 5, 2025. The contract is not set aside for any special designation. AmerisourceBergen Drug Corp holds a significant $999,999,999.00...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB22FM33YDelivery Order
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the procurement of Mesalamine delayed-release tablets. The contract has a firm fixed price of $13,369.15 and an ultimate completion date of December 17, 2021. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which serves as a critical supplier of pharmaceutical products and medical supplies to the Department of Defense and Department of Veterans Affairs healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, to deliver a comprehensive range of pharmaceutical and medical commodities in support of military and veteran healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 12/16/21 |